Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookStandard Treatment Guidelines (STG) and The National Essential Drug List for Tanzania (NEDLIT) (WHO; 1997; 210 pages)
View the documentFOREWORD
View the documentACKNOWLEDGMENTS
View the documentINTRODUCTION
close this folderStandard Treatment Guidelines (STG)
Open this folder and view contents1. GASTROINTESTINAL CONDITIONS
Open this folder and view contents2. RESPIRATORY DISEASES
Open this folder and view contents3. OBSTETRIC AND GYNAECOLOGICAL CONDITIONS AND CONTRACEPTION
Open this folder and view contents4. CARDIOVASCULAR DISEASES
Open this folder and view contents5. MALARIA
Open this folder and view contents6. SKIN DISEASES
Open this folder and view contents7. SEXUALLY TRANSMITTED INFECTIONS / DISEASES (STD)
Open this folder and view contents8. DENTAL AND ORAL CONDITIONS
Open this folder and view contents9. GENITO-URINARY DISEASES: KIDNEY CONDITIONS
Open this folder and view contents10. EAR, NOSE AND THROAT CONDITIONS
Open this folder and view contents11. EYE CONDITIONS
Open this folder and view contents12. TUBERCULOSIS AND LEPROSY
Open this folder and view contents13. MUSCULOSKELETAL CONDITIONS AND JOINT DISEASES
close this folder14. METABOLIC AND ENDOCRINE SYSTEM CONDITIONS
View the document14.1 Diabetes Mellitus
close this folder14.2 Thyroid Diseases
View the document14.2.1 Hyperthyroidism
View the document14.2.2 Hypothyroidism
Open this folder and view contents15. CENTRAL NERVOUS SYSTEM DISEASE CONDITIONS
Open this folder and view contents16. OTHER DISEASE CONDITIONS
Open this folder and view contents17. VIRAL INFECTIONS
Open this folder and view contents18. ALLERGIC REACTIONS
Open this folder and view contents19. NUTRITIONAL AND HAEMATOLOGIC CONDITIONS
Open this folder and view contents20. MALIGNANT DISEASE CONDITIONS
Open this folder and view contents21. INJURIES AND TRAUMA
View the document22. FOREIGN BODIES
View the document23. PAIN
View the document24. POISONING
View the document25. NORMAL LABORATORY VALUES
Open this folder and view contentsNATIONAL ESSENTIAL DRUG LIST
View the documentABBREVIATIONS AND SYMBOLS
 

14.2 Thyroid Diseases

Clinical features: Diseases of the thyroid gland are manifested by qualitative or quantitative alterations in hormone secretion or enlargement of the thyroid gland or both. Enlargement of the thyroid gland may result in normal increased, or decreased hormone secretion.

Treatment Guidelines

Iodised salt may not provide sufficient iodine and should therefore not be prescribed alone

Lugol's solution is too concentrated for daily use, and should be diluted by a factor of 30 to give 4.2 mg/ml (Schiller's iodine).


Treatment

Age under 45 years

First choice

Schiller's iodine 2 drops (460 micrograms) once daily for one year. Response may be obtained within 6 months

Second choice

Lugol's solution 3 drops (21 mg) once each month for up to one year. Lugol's solution is stronger then schiller's iodine (see above).

Third choice

Patients within this age usually respond poorly to iodine treatment and there is a risk of iodine induced thyrotoxicosis. Iodine therapy is therefore not recommended

 

Iodine oil capsules

Post thyroidectomy

Iodine should be given daily indefinitely to prevent recurrence, following dosing schedule give above

On Iodine use:

• Physiological doses of iodine can be given even in pregnancy. It is actually necessary to provide the therapy to avoid iodine deficiency to the foetus

• Patients should continue taking iodised salt indefinitely (Ref. National Policy on Nutrition) after the completion of treatment or begin giving 1 drop (7 mg) of Lugol's sol. per month.

• All salts in Tanzania should be iodized (Govt.law)

to previous sectionto next section

Please provide your feedback
Abbreviations
English  |  French